Regeneron (REGN) Lags Q1 Earnings and Revenue Estimates

Company Performance - Regeneron reported quarterly earnings of $8.22 per share, missing the Zacks Consensus Estimate of $8.43 per share, and down from $9.55 per share a year ago, representing an earnings surprise of -2.49% [1] - The company posted revenues of $3.03 billion for the quarter, missing the Zacks Consensus Estimate by 7.53%, and down from $3.15 billion year-over-year [2] - Over the last four quarters, Regeneron has surpassed consensus EPS estimates three times and topped consensus revenue estimates three times [2] Stock Outlook - Regeneron shares have declined approximately 14.3% since the beginning of the year, compared to a 6% decline in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $10.12 on revenues of $3.52 billion, and for the current fiscal year, it is $38.75 on revenues of $14.32 billion [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Regeneron belongs, is currently in the top 31% of over 250 Zacks industries, indicating a favorable industry outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that the industry outlook can significantly impact stock performance [5][8]